[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @PeptidreamInc PeptiDream Inc. PeptiDream Inc. posts on X about $4587t, longterm, japan the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1879416454778613760/interactions)  - X Week XXX +12% - X Month XXX +457% - X Months XXXXX +624% ### Mentions: X [#](/creator/twitter::1879416454778613760/posts_active)  - X Week X no change - X Month X -XX% - X Months XX +175% ### Followers: XX [#](/creator/twitter::1879416454778613760/followers)  - X Week XX no change - X Month XX +8.30% - X Months XX +189% ### CreatorRank: undefined [#](/creator/twitter::1879416454778613760/influencer_rank)  ### Social Influence [#](/creator/twitter::1879416454778613760/influence) --- **Social category influence** [countries](/list/countries) XXXX% **Social topic influence** [$4587t](/topic/$4587t) #1, [longterm](/topic/longterm) 9.09%, [japan](/topic/japan) XXXX% **Top accounts mentioned or mentioned by** [@peptidream_inc](/creator/undefined) ### Top Social Posts [#](/creator/twitter::1879416454778613760/posts) --- Top posts by engagements in the last XX hours "Our CFO Dr. Kaneshiro spoke at Panel Session X of the NIKKEI Drug Discovery Ecosystem Summit. He shared insights into our growth strategy and global pharma partnerships. 📺 Watch the full session here" [X Link](https://x.com/PeptidreamInc/status/1942114675157852374) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-07-07T06:53Z XX followers, XXX engagements "Today we released our Q2 earnings report which includes two significant capital investments to support our long-term growth and expansion strategy" [X Link](https://x.com/PeptidreamInc/status/1953711133107315108) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-08-08T06:53Z XX followers, XXX engagements "📹We are excited to announce that we will be presenting the Group's proprietary program PD-32766 at #EANM25 this weekend PD-32766 is a peptide-based theranostic agent targeting CA9 currently under development for ccRCC. #radiopharmaceutical #theranostics #RCC #CA9 #CAIX" [X Link](https://x.com/PeptidreamInc/status/1973572206572740679) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-10-02T02:14Z XX followers, XXX engagements "We started the development of 64Cu-PSMA-I&T for advanced prostate cancer as part of a registrational trial in Japan. In parallel we are also planning to start a clinical trial for its therapeutic pair 117Lu-PSMA-I&T. Press" [X Link](https://x.com/PeptidreamInc/status/1980128743059529796) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-10-20T04:27Z XX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
PeptiDream Inc. posts on X about $4587t, longterm, japan the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Social category influence countries XXXX%
Social topic influence $4587t #1, longterm 9.09%, japan XXXX%
Top accounts mentioned or mentioned by @peptidream_inc
Top posts by engagements in the last XX hours
"Our CFO Dr. Kaneshiro spoke at Panel Session X of the NIKKEI Drug Discovery Ecosystem Summit. He shared insights into our growth strategy and global pharma partnerships. 📺 Watch the full session here"
X Link @PeptidreamInc 2025-07-07T06:53Z XX followers, XXX engagements
"Today we released our Q2 earnings report which includes two significant capital investments to support our long-term growth and expansion strategy"
X Link @PeptidreamInc 2025-08-08T06:53Z XX followers, XXX engagements
"📹We are excited to announce that we will be presenting the Group's proprietary program PD-32766 at #EANM25 this weekend PD-32766 is a peptide-based theranostic agent targeting CA9 currently under development for ccRCC. #radiopharmaceutical #theranostics #RCC #CA9 #CAIX"
X Link @PeptidreamInc 2025-10-02T02:14Z XX followers, XXX engagements
"We started the development of 64Cu-PSMA-I&T for advanced prostate cancer as part of a registrational trial in Japan. In parallel we are also planning to start a clinical trial for its therapeutic pair 117Lu-PSMA-I&T. Press"
X Link @PeptidreamInc 2025-10-20T04:27Z XX followers, XX engagements
/creator/twitter::PeptidreamInc